Status | Study |
Recruiting |
Study Name: Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors Condition: Malignant Peripheral Nerve Sheath Tumors Date: 2017-04-13 |
Active, not recruiting |
Study Name: Use of Topical Liquid Diclofenac Following Laser Microporation of Cutaneous Neurofibromas in Patients With NF1 Condition: Neurofibromatosis 1 Cutaneous Neurofibroma Date: 2017-03-08 Interventions: Drug: Diclofenac Sodium Follow |
Not yet recruiting |
Study Name: Study of CPI-0610 in Patients With Malignant Peripheral Nerve Sheath Tumors Condition: Peripheral Nerve Tumors Date: 2016-11-21 Interventions: Drug: CPI-0610 Optional tu |
Recruiting |
Study Name: Photodynamic Therapy for Benign Dermal Neurofibromas Condition: NEUROFIBROMATOSIS 1 Date: 2016-03-25 Interventions: Procedure: PDT Treatment Drug: Levulan Kerastick |
Recruiting |
Study Name: A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery Condition: Malignant Peripheral Nerve Sheath Tumour (MPNST) Date: 2016-02-04 Interventions: Drug: Pembrolizumab Other Name: Keytruda |
Recruiting |
Study Name: Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (PNs) Condition: Neurofibromatosis 1 Plexiform Neurofibromas Date: 2015-09-05 |
Recruiting |
Study Name: Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas Condition: Plexiform Neurofibromas Date: 2014-06-25 Interventions: Drug: Imatinib Mesylate oral administration Other Na |
Recruiting |
Study Name: Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations Condition: Cancer Date: 2014-04-24 Interventions: Drug: Trametinib Trametinib is |
Active, not recruiting |
Study Name: Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 (16 Years +) Condition: NF1 Neurofibromatosis Plexiform Neurofibromas Date: 2014-03-14 Interventions: Drug: Cabozantinib Open label Phase II clinical trials. All subjects will start cabozantinib at 40 mg. S |
Active, not recruiting |
Study Name: PET/MRI in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1) Condition: Neurofibromatosis-1 Optic Glioma Plexiform Neurofibroma Date: 2013-02-25 |